CM/TNS/24/5719 - NHS National Framework for the supply of Pomalidomide
NHS England · awarded 20 February 2025 · delivered in East Midlands
Who
| Buyer | NHS England Runcorn, Cheshire |
|---|---|
| Suppliers |
Amarox Limited Grindeks Kalceks UK Ltd Thornton and Ross Ltd Wockhardt UK Limited Zentiva Pharma UK Ltd |
| Category | goods |
| Classification | Pharmaceutical products CPV 33600000 |
| Notice published | 11 March 2025 |
What it is for
Project title: NHS National Framework for the supply of Pomalidomide commencing 1 April 2025 Offer reference number: CM/TNS/24/5719 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5719/01 - Pomalidomide Lot 1 CESW: 01/04/2025 to 31/05/2026 Lot 2 LSNE: 01/04/2025 to 31/05/2026 Lot 3 NWLN: 01/04/2025 to 31/05/2026 Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Read the original award notice on Contracts Finder →
Other contracts from this buyer
1269 awards on file, worth £50.2bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 4 Mar 2026 | New Hospital Programme - Hospital 2.0 Alliance (H2A) FrameworkEngland | NHS England | Willmott Dixon Construction Limited +9 | £37.0bn |
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 19 Dec 2024 | NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland | NHS England | CSL Behring UK Ltd +5 | £905.2m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
Everything NHS England has awarded →
Other contracts won by this supplier
6 awards on file, worth £2.7bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 22 Jul 2024 | NHS Branded Medicines Tranche Framework for London and South of EnglandEast Midlands | NHS England | Sun Pharma UK Ltd +28 | £381.0m |
| 20 Feb 2025 | CM/TNS/24/5719 - NHS National Framework for the supply of PomalidomideEast Midlands | NHS England | Zentiva Pharma UK Ltd +4 | £17.1m |
| 30 Sep 2024 | NHS National Framework for Transition products commencing 1 October 2024East Midlands | NHS England | Thornton and Ross Ltd +11 | £16.2m |